Plain-English translation of NCT06228456 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a lower dose of ticagrelor, a blood-thinning medication, works better than the standard medication at preventing heart complications after a planned heart stent procedure. The study focuses on patients who have been identified as at higher risk for blood clots using a special scoring tool that looks at your age, weight, kidney function, diabetes, and genetic factors. The goal is to see if this medication can reduce heart damage and complications after the procedure.
Many patients taking don't respond to it as well as needed, which can lead to dangerous blood clots and heart damage after a stent procedure. This medication may provide stronger protection against these complications, especially for people at higher risk.
You likely qualify if…
You likely don't qualify if…
After your stent procedure, you will be randomly assigned to either continue taking or switch to the lower-dose ticagrelor medication. You will take your assigned blood-thinning medication along with aspirin, and the research team will monitor how well your blood platelets respond to the treatment to see which medication works better at preventing complications.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States